# Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

> **NCT01431898** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 82 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** GS-9669 tablets
- **DRUG:** Placebo to Match GS-9669 tablet

## Key facts

- **NCT ID:** NCT01431898
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-05
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2012-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01431898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01431898, "Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01431898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*